ULTRAGENYX PHARMACEUTICAL INC. Prepaid Expense and Other Assets, Current
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Prepaid Expense and Other Assets, Current of $55.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-05
- 2026-06-30: Prepaid Expense and Other Assets, Current $55.00M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $68.00M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $61.00M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $53.22M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $55.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $68.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $61.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $53.22M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $61.24M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $59.84M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $40.00M 10-K · filed 2026-02-18 | $40.29M 10-K · filed 2025-02-19 |
| 2023-12-31 | $47.62M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $46.03M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $51.38M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $67.38M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $68.93M 10-Q · filed 2023-11-03 | |
| 2022-09-30 | $70.98M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $77.46M 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $63.02M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $71.75M 10-K · filed 2023-02-17 | |
| 2021-09-30 | $69.19M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $63.93M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $68.03M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $57.63M 10-K · filed 2022-02-15 | |
| 2020-09-30 | $64.26M 10-Q · filed 2020-10-27 | |
| 2020-06-30 | $58.20M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $64.79M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $51.40M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $49.17M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $46.61M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $44.99M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $42.86M 10-K · filed 2020-02-14 | |
| 2018-09-30 | $49.67M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $36.84M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $33.95M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $29.16M 10-K · filed 2019-02-20 | $28.70M 10-K · filed 2018-02-21 |
| 2017-09-30 | $19.38M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $19.68M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $19.22M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $20.14M 10-K · filed 2018-02-21 | |
| 2016-09-30 | $18.94M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $17.80M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $17.09M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $13.06M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $12.32M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $9.43M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $6.88M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $5.93M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $5.55M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $4.95M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $4.24M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $1.85M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |